期刊
FRONTIERS IN MEDICINE
卷 5, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2018.00137
关键词
GAS6; TYRO3; AXL; MERTK; platelet activation; signaling pathways
资金
- National Hemophilia Foundation/Baxter Clinical Research Fellowship
- American Society of Hematology Scholar Award
- Hemostasis, and Thrombosis Research Society Mentored Research Award (HTRS-MRA)
- CSL Behring
- NIH [K12HD068372-03, R01HL084086, R01HL120728]
- Postle Family Chair of Pediatric Cancer and Blood Disorders
- HRSA/MCHB [5H30MC00008-20-00]
The GAS6/TYRO3-AXL-MERTK (TAM) signaling pathway is essential for full and sustained platelet activation, as well as thrombus stabilization. Inhibition of this pathway decreases platelet aggregation, shape change, clot retraction, aggregate formation under flow conditions, and surface expression of activation markers. Transgenic mice deficient in GAS6, or any of the TAM family of receptors that engage this ligand, exhibit in vivo protection against arterial and venous thrombosis but do not demonstrate either spontaneous or prolonged bleeding compared to their wild-type counterparts. Comparable results are observed in wild-type mice treated with pharmacological inhibitors of the GAS6-TAM pathway. Thus, GAS6/TAM inhibition offers an attractive novel therapeutic option that may allow for a moderate reduction in platelet activation and decreased thrombosis while still permitting the primary hemostatic function of platelet plug formation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据